Hong Kong Island, Hong Kong, China Everbright appeared to be the Corporate Investor, which was created in 1997. The venture was found in Asia in Hong Kong. The main department of described Corporate Investor is located in the Hong Kong.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Everbright, startups are often financed by Versant Ventures, Venrock, Tavistock Life Sciences. The meaningful sponsors for the fund in investment in the same round are IDG Capital, Source Code Capital, HOPU Investment Management Company. In the next rounds fund is usually obtained by JD.com, Warburg Pincus, WANDA Group.
The fund has specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Terminus Technologies, Ambrx, Googut Wine & Spirits. Among the most popular fund investment industries, there are Video Streaming, Health Care. For fund there is no match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
The important activity for fund was in 2019. Speaking about the real fund results, this Corporate Investor is 15 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in 2-6 investment rounds annually. The typical startup value when the investment from Everbright is more than 1 billion dollars. This Everbright works on 19 percentage points less the average amount of lead investments comparing to the other organizations.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Centrecourt Asset Management | New York, New York, United States |
| Charme Capital Partners | Italy, Lombardia, Milano |
| Digital Surgeons | Connecticut, New Haven, United States |
| DK Gate | Japan, Tokyo |
| FortisBC | British Columbia, Canada, Surrey |
| Galapagos | Belgium, Limburg, Mechelen-bovelingen |
| Galitt | Boulogne-Billancourt, France, Ile-de-France |
| Impression Ventures | Canada, Ontario, Toronto |
| Karst Peak Capital | China, Hong Kong, Hong Kong Island |
| Newlight Management | New York, New York, United States |
| Planeta Securitizadora Agro | Brazil, São Paulo, Sao Paulo |
| Portage Biotech | Canada, Ontario, Toronto |
| RFF Vest | - |
| Rohatton | - |
| Sightline Healthcare Opportunity | - |
| Tokio Marine Capital | Chiyoda, Japan |
| ULIXE Group | Italy, Piemonte, Torino |
| Warisan Investment Partners | Switzerland, Zug, Zug |
| Zhaopin | Beijing, Beijing, China |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Reforgene Medicine | $15M | 28 Apr 2023 | Guangzhou, Guangdong, China | ||
Grit Science | $15M | 02 Mar 2022 | - | ||
Innogen Pharmaceutical | $120M | 23 Dec 2021 | Shanghai, Shanghai, China | ||
Jiuduuoduo | $16M | 29 Oct 2021 | - | ||
IASO Biotherapeutics | $108M | 16 Sep 2021 | Xuanwu District, Jiangsu, China | ||
Dedao | $3M | 29 Oct 2020 | Hebei, Hebei, China | ||
T11 Food Market | $14M | 27 Apr 2020 | Dongcheng District, Beijing, China | ||
Yeelight | $28M | 16 Apr 2020 | China, Wuwei | ||
Juvenile Get | $15M | 14 Nov 2019 | - |
– IASO Biotherapeutics announced the completion of $108m Series C to advance the global development of novel cell therapies and biologics for oncology and autoimmune diseases.
– The round was led by CDH Baifu, and followed by CCB International, with strong participation from Everbright Limited, Co-Stone Capital, CNCB Capital and Plaisance Capital.
– Current shareholder GL Ventures also participated.
– Since its founding in 2017, IASO Bio has raised more than $178m.
– Proceeds from the financing will be used to accelerate the global development and regulatory submissions of multiple novel cell therapies.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Reforgene Medicine | $15M | 28 Apr 2023 | Guangzhou, Guangdong, China | ||
Grit Science | $15M | 02 Mar 2022 | - | ||
Innogen Pharmaceutical | $120M | 23 Dec 2021 | Shanghai, Shanghai, China | ||
Jiuduuoduo | $16M | 29 Oct 2021 | - | ||
IASO Biotherapeutics | $108M | 16 Sep 2021 | Xuanwu District, Jiangsu, China | ||
Dedao | $3M | 29 Oct 2020 | Hebei, Hebei, China | ||
T11 Food Market | $14M | 27 Apr 2020 | Dongcheng District, Beijing, China | ||
Yeelight | $28M | 16 Apr 2020 | China, Wuwei | ||
Juvenile Get | $15M | 14 Nov 2019 | - |
